Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Clinical course and classification of multiple sclerosis

Michael J Olek, DO
Section Editor
Francisco González-Scarano, MD
Deputy Editor
John F Dashe, MD, PhD


Multiple sclerosis (MS) is most common immune-mediated inflammatory demyelinating disease of the central nervous system. The clinical course and classification of MS will be reviewed here. Other aspects of MS are discussed separately:

(See "Pathogenesis and epidemiology of multiple sclerosis".)

(See "Clinically isolated syndromes suggestive of multiple sclerosis".)

(See "Clinical features of multiple sclerosis in adults".)

(See "Diagnosis of multiple sclerosis in adults".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Nov 08, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83:278.
  2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46:907.
  3. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36 Suppl:S6.
  4. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2003; 9:260.
  5. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73:1996.
  6. Rice CM, Cottrell D, Wilkins A, Scolding NJ. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry 2013; 84:1100.
  7. Khaleeli Z, Ciccarelli O, Mizskiel K, et al. Lesion enhancement diminishes with time in primary progressive multiple sclerosis. Mult Scler 2010; 16:317.
  8. Kremenchutzky M, Rice GP, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129:584.
  9. Kurtzke JF. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand 1970; 46:493.
  10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444.
  11. Kister I, Chamot E, Salter AR, et al. Disability in multiple sclerosis: a reference for patients and clinicians. Neurology 2013; 80:1018.
  12. Scalfari A, Neuhaus A, Daumer M, et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol 2013; 70:214.
  13. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430.
  14. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004; 56:303.
  15. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66:172.
  16. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74:2004.
  17. Koch M, Kingwell E, Rieckmann P, et al. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1039.
  18. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129:595.
  19. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116 ( Pt 1):117.
  20. University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80:499.
  21. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007; 256 Suppl 1:S5.
  22. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252 Suppl 3:iii15.
  23. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133:1914.
  24. Bejaoui K, Rolak LA. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 2010; 74:900.
  25. Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004; 328:731.
  26. Goodin DS, Ebers GC, Johnson KP, et al. The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999; 52:1737.
  27. Buljevac D, Hop WC, Reedeker W, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ 2003; 327:646.
  28. Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis. Neurology 2013; 81:184.
  29. Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry 2016; 87:324.
  30. GEORGI W. [Multiple sclerosis. Anatomopathological findings of multiple sclerosis in diseases not clinically diagnosed]. Schweiz Med Wochenschr 1961; 91:605.
  31. Mackay RP, Hirano A. Forms of benign multiple sclerosis. Report of two "clinically silent" cases discovered at autopsy. Arch Neurol 1967; 17:588.
  32. Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983; 40:533.
  33. Phadke JG, Best PV. Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy. J Neurol Neurosurg Psychiatry 1983; 46:414.
  34. Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand 1989; 79:428.
  35. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20:17.
  36. Rovaris M, Barkhof F, Calabrese M, et al. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology 2009; 72:1693.
  37. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology 2007; 68:496.
  38. Gholipour T, Healy B, Baruch NF, et al. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology 2011; 76:1996.
  39. Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84:1192.
  40. Swanton J, Fernando K, Miller D. Early prognosis of multiple sclerosis. Handb Clin Neurol 2014; 122:371.
  41. Leibowitz U, Alter M. Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand 1970; 46:53.
  42. Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. J Chronic Dis 1977; 30:819.
  43. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227.
  44. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103:281.
  45. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999; 122 ( Pt 4):641.
  46. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67:148.
  47. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129:606.
  48. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63:1686.
  49. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126:770.
  50. Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 2011; 68:1514.
  51. Klawiter EC. Current and new directions in MRI in multiple sclerosis. Continuum (Minneap Minn) 2013; 19:1058.
  52. Schlaeger R, Papinutto N, Zhu AH, et al. Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurol 2015; 72:897.
  53. Bernitsas E, Bao F, Seraji-Bozorgzad N, et al. Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes. Mult Scler Relat Disord 2015; 4:47.
  54. Schlaeger R, Papinutto N, Panara V, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014; 76:568.
  55. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158.
  56. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006; 66:1384.
  57. MacKenzie-Graham A, Kurth F, Itoh Y, et al. Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol 2016; 73:944.
  58. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004; 63:2039.
  59. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107.
  60. Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan. J Neurol Sci 2013; 330:52.
  61. Titelbaum DS, Degenhardt A, Kinkel RP. Anti-tumor necrosis factor alpha-associated multiple sclerosis. AJNR Am J Neuroradiol 2005; 26:1548.